Eu­ro­pean Com­mis­sion clears As­traZeneca's $39B bid for Alex­ion and a fu­ture in rare dis­eases. Now there's just a fi­nal hur­dle

As­traZeneca has cleared the penul­ti­mate hur­dle be­fore of­fi­cial­ly com­plet­ing its $39 bil­lion ac­qui­si­tion of Alex­ion.

The Eu­ro­pean Com­mis­sion has giv­en its bless­ing to the pro­posed deal af­ter a re­view, the lat­est green light fol­low­ing clear­ances by the Unit­ed States’ FTC and its coun­ter­parts in 11 coun­tries. The UK’s CMA will be the last one to de­cide — and it has un­til Ju­ly 21.

As­sum­ing an OK, As­traZeneca has pre­vi­ous­ly said it ex­pects to close the deal in Q3.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN